A Golden Era for Pharma in 2020 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Golden Era for Pharma in 2020



More favourable conditions for the pharmaceutical industry, including a “golden era of renewed productivity and prosperity” have been forecast in a new report from analyst firm PricewaterhouseCoopers (PwC). According to the report, major scientific and technological advances, coupled with sociodemographic changes, increasing demand for medicines and trade liberalism, will help to transform the industry’s fortunes in 2020.

The report explains that there are three major challenges facing the industry at the moment: rising customer expectations, poor scientific productivity, and prevailing management culture, mental models and strategies that companies still rely on.

In addition, the report explains that there is a need to alter the concept of healthcare. Several industry trends have converged to increase the costs of healthcare and a proposed model is to focus on curing or preventing disease rather than treating it.

Several steps are described that pharmaceutical companies can take to ensure they make it through the challenges ahead and survive until 2020:

  • Provide real-world data on medicines’ outcomes. Pooling data can provide vast knowledge about disease states and patient populations.
  • Decide how much to invest in growth markets. The biggest markets may not be the most profitable ones. In addition, the costs of setting up local manufacturing may outweigh additional custom.
  • Consider the implications of investing in new treatment types, such as vaccines and regenerative medicines. Be selective about the diseases approached.
  • Invest more heavily in genetics and genomics, and revise R&D processes. Knowledge of genetics and genomics can lead to more effective personalised medicines.
  • Collaborate with academia, government and nongovernment organisations, and other companies to access the best science and expertise.
  • Companies need to focus on innovation that addresses the needs of patients, payers and providers.

The report, From Vision to Decision Pharma 2020, can be downloaded for free from PricewaterhouseCoopers .

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here